Investigations Launched into Mergers and Acquisitions by Monteverde & Associates PC
PorAinvest
viernes, 25 de julio de 2025, 5:33 pm ET1 min de lectura
CRGX--
One of the key cases involves CARGO Therapeutics, Inc. (NASDAQ: CRGX), which was sold to Concentra Biosciences, LLC for $4.379 per share, plus one non-transferable contingent value right. The contingent value right entitles shareholders to 100% of the closing net cash of CARGO in excess of $217.5 million, and 80% of the net proceeds from the sale, license, or other disposition of certain product candidates within two years following the closing [3].
Monteverde & Associates is also investigating Hudson Global, Inc. (HSON) in relation to its merger with Star Equity Holdings, Inc. Under the terms of this transaction, each share of Hudson will be converted into a right to receive $4.50 in cash and 0.05 shares of Star Equity common stock [3].
Additionally, the firm is looking into Breeze Holdings Acquisition Corp.'s merger with YD Biopharma Limited. The specifics of this merger are not provided in the available source materials, but Monteverde & Associates is seeking to ensure that shareholders are protected and compensated appropriately [3].
Lastly, the firm is investigating Enzo Biochem's sale to Battery Ventures. The terms of this deal are also not detailed in the source materials, but the firm is committed to protecting the interests of Enzo's shareholders [3].
Monteverde & Associates PC has a successful track record in recovering money for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm encourages shareholders who have concerns about these mergers to visit their website or contact Juan Monteverde, Esq., via e-mail at or by telephone at (212) 971-1341 for more information.
References:
[1] https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-launches-legal-inquiry-for-the-merger-tlgyf-efin-cepo-and-sqcf-302514182.html
[2] https://www.ainvest.com/news/strategic-rationale-valuation-implications-concentra-biosciences-acquisition-iteos-therapeutics-2507/
[3] https://www.marketscreener.com/news/the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-crgx-hson-brzh-and-enzb-ce7c5fdbdc80f525
HSON--
ITOS--
STRR--
Monteverde & Associates PC is investigating several mergers and acquisitions, including CARGO Therapeutics' sale to Concentra Biosciences, Hudson Global's merger with Star Equity Holdings, Breeze Holdings Acquisition Corp.'s merger with YD Biopharma Limited, and Enzo Biochem's sale to Battery Ventures. The firm is seeking to recover money for shareholders and encourages them to contact them for more information.
New York, July 2, 2025 — Monteverde & Associates PC, a leading securities class action law firm, has initiated legal inquiries into several high-profile mergers and acquisitions (M&A) transactions. The firm is seeking to recover money for shareholders affected by these deals and has encouraged them to contact the firm for more information.One of the key cases involves CARGO Therapeutics, Inc. (NASDAQ: CRGX), which was sold to Concentra Biosciences, LLC for $4.379 per share, plus one non-transferable contingent value right. The contingent value right entitles shareholders to 100% of the closing net cash of CARGO in excess of $217.5 million, and 80% of the net proceeds from the sale, license, or other disposition of certain product candidates within two years following the closing [3].
Monteverde & Associates is also investigating Hudson Global, Inc. (HSON) in relation to its merger with Star Equity Holdings, Inc. Under the terms of this transaction, each share of Hudson will be converted into a right to receive $4.50 in cash and 0.05 shares of Star Equity common stock [3].
Additionally, the firm is looking into Breeze Holdings Acquisition Corp.'s merger with YD Biopharma Limited. The specifics of this merger are not provided in the available source materials, but Monteverde & Associates is seeking to ensure that shareholders are protected and compensated appropriately [3].
Lastly, the firm is investigating Enzo Biochem's sale to Battery Ventures. The terms of this deal are also not detailed in the source materials, but the firm is committed to protecting the interests of Enzo's shareholders [3].
Monteverde & Associates PC has a successful track record in recovering money for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm encourages shareholders who have concerns about these mergers to visit their website or contact Juan Monteverde, Esq., via e-mail at or by telephone at (212) 971-1341 for more information.
References:
[1] https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-launches-legal-inquiry-for-the-merger-tlgyf-efin-cepo-and-sqcf-302514182.html
[2] https://www.ainvest.com/news/strategic-rationale-valuation-implications-concentra-biosciences-acquisition-iteos-therapeutics-2507/
[3] https://www.marketscreener.com/news/the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-crgx-hson-brzh-and-enzb-ce7c5fdbdc80f525

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios